To overcome the developed tumor resistance for the first- and second-generation EGFR TKIs, Sun et al. synthesized a novel series of tricyclic oxazine fused quinazoline derivatives as dual HER2 and EGFR inhibitors with an irreversible binding mode. The gene discussed is ERBB2; the disease is neoplasm.